BNTX Stock Analysis: Buy, Sell, or Hold?
BNTX - BioNTech SE American Depositary Share
$97.55
3.63 (3.86%)
▲
5d:
+8.38%
30d:
+9.43%
90d:
+9.09%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When BNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BNTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BNTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BNTX is currently trading at $97.55, which is considered extended relative to its 30-day fair value range of $88.14 to $93.67.
Technical Outlook: Technically, BNTX is in a downtrend. The price is approaching resistance at $98.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: BNTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $121.80 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BNTX is in a downtrend. The price is approaching resistance at $98.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: BNTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $121.80 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$88.14 -
$93.67
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 24.9% below Wall St target ($121.80)
Trading Range Analysis
30-Day Trading Range
$88.14 -
$93.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$88.83
Resistance Level
$98.81
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.04
Wall Street Target
$121.80
(+24.9%)
Revenue Growth (YoY)
-35.4%
Earnings Growth (YoY)
-43.2%
Profit Margin
-44.6%
Share & Embed Analysis
Last updated: July 03, 2026 3:55 PM ET
Data refreshes hourly during market hours. Next update: 4:55 PM
Data refreshes hourly during market hours. Next update: 4:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sierk Poetting
SELL
50000 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$291 | 63 BUY |
